Tandem t:slim X2 pump with Control-IQ AID cleared for EU use with Lyumjev

Tandem have announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now cleared for use with Lyumjev® ultra-rapid acting insulin in theEU.

Despite Lyumjev gaining approval in the EU back in 2020, Tandem Diabetes Care’s t:slim X2 insulin pump needed more time to pass the stringent testing required for compatibility. The collaboration between Eli Lilly and Tandem focused on ensuring that Lyumjev, Eli Lilly’s ultra-rapid acting insulin, could seamlessly work with Tandem's insulin delivery system.

In a press release revealing the EU’s recent approval, Jordan Pinsker, Chief Medical Officer at Tandem, emphasised the significance of this milestone.

“Ultra-rapid acting insulin is a popular choice for people living with diabetes due to its fast response time," Pinsker said. "We’re proud to offer Lyumjev compatibility with our t:slim X2 pump as part of an AID system in the EU, providing more flexibility for our customers in these countries.”

This partnership now gives people in the EU more options to manage their diabetes with greater efficiency and convenience, combining the fast-acting benefits of Lyumjev with the advanced technology of the t:slim X2 pump.

Reference

Tandem/Business Wire: https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-tslim-x2-insulin-pump-now-compatible-lyumjev-ultra-rapid